Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial
April 15 (Reuters) - BioCardia Inc BCDA.O:
BIOCARDIA ANNOUNCES POSITIVE DSMB REVIEW OF CARDIALLO ALLOGENEIC CELL THERAPY FOR HEART FAILURE PHASE 1/2 CLINICAL TRIAL
BIOCARDIA INC: PLANS TO PROGRESS TRIAL TO ENROLLMENT OF 39 PARTICIPANTS IN UNITED STATES
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Microsoft 2026 Q3 Earnings Preview: Can Azure’s Growth Momentum Keep Up With Massive AI Capital Spending?

Deep Analysis 48 Hours Before Microsoft Earnings: OpenAI Agreement Restructuring Implemented, Three Variables of Azure, Copilot, and Capital Expenditure Determine MSFT Valuation Recovery Path

MSTR Stock Price Prediction 2026-2030: Is Strategy the Ultimate Bitcoin Leveraged Play?

SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Nvidia Shares Hit Record High, Market Cap Tops $526 Trillion, How Much Higher Can It Go Amid AI Capex Boom?

Tradingkey







